Compounds for targeting endothelial cells, compositions containing the same and methods for their use
The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.
1. A compound having the following structure:
optionally conjugated to a substrate.
2. A method of synthesizing the compound of claim 1 , comprising the following steps:
(a) reacting Diacid with HATU and NAHCO 3 to yield an Fmoc tetramer;
(b) dissolving said Fmoc tetramer in acetonitrile to yield a crude amine; and
(c) treating the crude amine with dichloromethane to yield D50.
3. A composition comprising the compound of claim 1 conjugated to a nanoparticle.
4. A composition for use in targeting endothelial cells, tumor cells or other cells which express NP-1, which comprises a compound of claim 3 .
5. A method of imaging an angiogenic site expressing NP-1 in a human or animal comprising administering to said human or animal a composition of claim 3 , optionally further comprising a detectable moiety.
6. A method of imaging endothelial cells, tumor cells or other cells that express NP-1 in a human or animal comprising administering to said human or animal a composition of claim 3 , optionally further comprising a detectable moiety.
7. A method for the therapeutic delivery in vivo of one or more nanoparticles to a patient suffering from effects associated with an angiogenesis-related disorder associated with NP-1 expression comprising administering a therapeutically effective amount of a composition of claim 3 .
8. A method of treating an individual exhibiting effects of a tumor or an angiogenesis-related disorder associated with NP-1 expression comprising administering a therapeutically effective amount of a composition of claim 3 , optionally further comprising a therapeutic moiety.
9. A compound having the following structure:
10. A method of synthesizing the structure of claim 9 , comprising the following steps:
(a) constructing a peptide sequence on preloaded H-Arg(Pmc)-O-2-chlrotrityl chloride resin;
(b) cleaving the peptide sequence from the resin; and
(c) isolating the peptide sequence.
11. A composition comprising the compound of claim 9 conjugated to a nanoparticle.
12. A composition for use in targeting endothelial cells, tumor cells or other cells which express NP-1, which comprises a compound of claim 9 .
13. A method of imaging an angiogenic site expressing NP-1 in a human or animal comprising administering to said human or animal a composition of claim 12 , optionally further comprising a detectable moiety.
14. A method of imaging endothelial cells, tumor cells or other cells that express NP-1 in a human or animal comprising administering to said human or animal a composition of claim 12 , optionally further comprising a detectable moiety.
15. A method for the therapeutic delivery in vivo of one or more nanoparticles to a patient suffering from effects associated with an angiogenesis-related disorder associated with NP-1 expression comprising administering a therapeutically effective amount of a composition of claim 12 .
16. A method of treating an individual exhibiting effects of a tumor or an angiogenesis-related disorder associated with NP-1 expression comprising administering a therapeutically effective amount of a composition of claim 12 , optionally further comprising a therapeutic moiety.
17. A method for treating a human or animal with a tumor or angiogenesis-related disease associated with NP-1 expression comprising administering to said human or animal a therapeutically effective amount of a composition according to claim 1 , wherein the composition is radiolabeled.
18. The method of claim 17 , wherein the tumor or angiogenesis-related disease is prostate cancer.
19. The method of claim 17 , wherein the composition further comprises a chelator.
20. A compound having the following structure:
21. A method of imaging a human or animal with prostate cancer expressing NP-1 comprising administering a detectable amount of a composition comprising the compound of claim 20 , and detecting the composition.